The first phase 3 readout with Spine BioPharma's drug candidate for chronic low back pain (CLBP) has proved disappointing, but the company still believes there is a way forward for the programme. The ...

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking an Ionis-partnered candidate that could offer dosing just once a year into pivotal trials on the strength of ...